To assess the performance of sABEv3.22 for inducible gene knockout, we targeted two genes expressing Beta-2 microglobulin (B2M) or CD46 regulatory proteins that have been widely studied in the context of allogeneic cell therapies and cancer research49–52. This evidence concerns the gene CD46 and cancer.